Tumor microenvironment responsive nano-platform for overcoming sorafenib resistance of hepatocellular carcinoma.

ABSTRACT: Hepatocellular carcinoma (HCC) is a malignant tumor, which seriously jeopardizes human health. The 5-year relative survival rate of HCC is only about 18%. Sorafenib, a small molecule multi-targeted tyrosine kinase inhibitor (MTKI), has been classified as the first-line treatment scheme for HCC and has significantly extended the median survival time for patients with advanced HCC. Nevertheless, the emergence of sorafenib resistance has substantially hampered its further clinical application. Herein, the nano-platform based on phototherapy and small molecular targeted therapy (SMTT) was devised to overcome the sorafenib resistance and reduce the adverse effects. Hollow mesoporous manganese dioxide (H-MnO₂) was prepared by hard template method, and the prepared H-MnO₂ wa

SUBMITTER: Xu W 

PROVIDER: S-EPMC10767498 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature